CNS PHARMACEUTICALS, INC. (CNSP) News

CNS PHARMACEUTICALS, INC. (CNSP): $0.25

(%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter CNSP News Items

CNSP News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

CNSP News Highlights

  • CNSP's 30 day story count now stands at 2.
  • Over the past 5 days, the trend for CNSP's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • CNS are the most mentioned tickers in articles about CNSP.

Latest CNSP News From Around the Web

Below are the latest news stories about CNS Pharmaceuticals Inc that investors may wish to consider to help them evaluate CNSP as an investment opportunity.

Maxim Group Keeps Their Buy Rating on CNS Pharmaceuticals (CNSP)

In a report issued on February 2, Jason McCarthy from Maxim Group maintained a Buy rating on CNS Pharmaceuticals (CNSP – Research Report), with a price target of $2.00. The company's shares closed last Friday at $0.44, close to its 52-week low of $0.42. According to TipRanks.com, McCarthy is ranked 0 out of 5 stars with an average return of -22.9% and a 14.7% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Appili Therapeutics Inc Class A, Reviva Pharmaceuticals Holdings, and Brainstorm Cell Therapeutics. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for CNS Pharmaceuticals.

Brian Anderson on TipRanks | February 6, 2022

WPD Pharmaceuticals Secures Berubicin Sub-License Rights in Perpetuity

Commercially Reasonable Development Expenditures of at least US$2,000,000 going towards the development, testing, regulatory approval or commercialization of the licensed product, Berubicin, during the applicable development periodVANCOUVER, British Columbia, Feb. 01, 2022 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (the “Company” or “WPD”) (CSE: WBIO) (FSE: 8SV1), announced that in respect to its sublicense agreement with CNS Pharmaceuticals, Inc. (the “CNS Agreement”) on December 23, 2021, CN

Yahoo | February 1, 2022

CNS Pharmaceuticals (CNSP) Investor Presentation - Slideshow

No summary available.

Seeking Alpha | January 26, 2022

Is CNS Pharmaceuticals, Inc. (CNSP) Outperforming Other Medical Stocks This Year?

Here is how CNS Pharmaceuticals, Inc. (CNSP) and Celyad SA (CYAD) have performed compared to their sector so far this year.

Yahoo | January 20, 2022

CNS Pharmaceuticals to Present at the Virtual Investor 2022 Top Picks Conference

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that John Climaco, Chief Executive Officer of CNS Pharmaceuticals, will participate in the Virtual Investor 2022 Top Picks Conference on Wednesday, January 26, 2022 at 11:00 AM ET.

Yahoo | January 20, 2022

JTC Team to Host Virtual Investor 2022 Top Picks Conference on January 25th, 26th, and 27th

\- Access the event and schedule of presenting companies at virtualinvestorco.com -\- Live video webcast presentations of participating companies followed by interactive Q&A session -PITTSTOWN, NJ / ACCESSWIRE / January 12, 2022 /JTC Team ("JTC"), a fully integrated corporate communications and investor relations firm, today announced it will host the Virtual Investor 2022 Top Picks Conference January 25-27, 2022.

Yahoo | January 12, 2022

CNS Pharmaceuticals Announces Closing of $11.5 Million Private Placement Priced At-the-Market Under Nasdaq Rules

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system (CNS), announced today the closing of its previously announced private placement priced at-the-market under Nasdaq rules of 12,105,264 shares of common stock (or pre-funded warrants in lieu thereof) and warrants to purchase up to an aggregate of 12,105,264 shares of common stoc

Yahoo | January 10, 2022

CNS Pharmaceuticals to Present at the H.C. Wainwright BioConnect Conference

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that John Climaco, Chief Executive Officer of CNS Pharmaceuticals, will present at the virtual H.C. Wainwright BioConnect Conference taking place January 10-13, 2022.

Yahoo | January 7, 2022

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

Good morning, trader!

William White on InvestorPlace | January 6, 2022

CNS Pharmaceuticals Announces $11.5 Million Private Placement Priced At-the-Market Under Nasdaq Rules

HOUSTON , Jan. 6, 2022 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP ) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system (CNS), announced today that it has entered into securities purchase agreements with several institutional and accredited investors to issue, in a private placement priced at-the-market under Nasdaq rules, 12,105,264 shares of common stock (or pre-funded warrants in lieu thereof) and warrants to purchase up to an aggregate of 12,105,264 shares of common stock, at a purchase price of $0.95 per share of common stock (or pre-funded warrant) and associated warrant, for expected gross proceeds to CNS of approximately $11.5 million , be...

Benzinga | January 6, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.2138 seconds.